Capdevila Jaume, Argiles Guillem, Rodriguez-Frexinos Victor, Nuñez Isaac, Tabernero Josep
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Discov Med. 2010 Feb;9(45):153-62.
Although thyroid carcinoma usually has an excellent prognosis, the lack of therapeutic options is an issue for patients that develop metastases and are resistant to radioiodine therapy. The development of novel molecular targeted therapies and the characterization of several proteins that have a crucial role in the carcinogenesis process of differentiated thyroid cancer have created an opportunity to design new clinical trials for this setting. Moreover, the encouraging initial results of first clinical trials have accelerated the development of placebo-controlled phase III studies that will assess the role of these new agents in the management of differentiated thyroid cancer.
尽管甲状腺癌通常预后良好，但对于发生转移且对放射性碘治疗耐药的患者而言，缺乏治疗选择仍是一个问题。新型分子靶向疗法的发展以及在分化型甲状腺癌致癌过程中起关键作用的几种蛋白质的特性研究，为针对这种情况设计新的临床试验创造了机会。此外，首批临床试验令人鼓舞的初步结果加速了安慰剂对照的III期研究的开展，这些研究将评估这些新药物在分化型甲状腺癌治疗中的作用。
